*Carcinoma Transitional Cell/pathology Female Humans Male Neoplasm Invasiveness Nephroureterectomy Sweden *Urinary Bladder Neoplasms/pathology Swedish national guidelines Urothelial carcinoma non-muscle invasive bladder cancer upper tract urothelial carcinoma

*Carcinoma Transitional Cell/drug therapy/pathology Cisplatin Female Humans Male *Urinary Bladder Neoplasms/drug therapy/pathology *Urology *Bladder cancer *European Association of Urology *Guidelines *Immunotherapy *Metastatic *Systemic therapy *Urothelial carcinoma

Humans *Urinary Bladder Neoplasms/diagnosis/therapy/pathology BCG Vaccine/therapeutic use Cystectomy Administration Intravesical Urinary Bladder/pathology Bcg Bladder Bladder tumours Cancer Carcinome urothélial Cystectomie Cytologie urinaire Survie Survival Tumeurs de la vessie Urine cytology Urothelial carcinoma Vessie

Antineoplastic Combined Chemotherapy Protocols/adverse effects Bayes Theorem *Carcinoma Transitional Cell/drug therapy/surgery Humans Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/surgery Ici Pd-1 Pd-l1 adjuvant therapy chemotherapy urothelial carcinoma

Relapse Survellance Transitional cell carcinoma Ureteral margin Urothelial carcinoma

Administration Intravesical *Antineoplastic Agents/therapeutic use BCG Vaccine/therapeutic use Humans Neoplasm Recurrence Local Quality of Life *Urinary Bladder Neoplasms/drug therapy Bacillus Calmette–Guérin bladder cancer chemotherapy health-related quality of life hyperthermia immunotherapy intravesical therapy non-muscle invasive bladder cancer urothelial carcinoma

Diffusion Magnetic Resonance Imaging Humans Magnetic Resonance Imaging/methods Muscles Sensitivity and Specificity Urinary Bladder/diagnostic imaging/pathology *Urinary Bladder Neoplasms/diagnostic imaging/pathology Vesical Imaging-Reporting and Data System multiparametric magnetic resonance imagine muscle-invasive bladder cancer staging urothelial carcinoma

*Carcinoma Transitional Cell/pathology/radiotherapy Humans *Kidney Neoplasms Kidney Pelvis/pathology Prognosis *Ureteral Neoplasms/pathology *Urinary Bladder Neoplasms Adjuvant radiotherapy Prognostic Radiotherapy Survival Upper urinary tract urothelial carcinoma

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.

Carcinoma Transitional Cell/pathology Disease-Free Survival Humans *Neoplasm Staging Prognosis Urinary Bladder/*pathology Urinary Bladder Neoplasms/*pathology Bladder urothelial carcinoma Meta-analysis Squamous differentiation

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.

Carcinogenesis/genetics/*immunology/pathology *Genetic Predisposition to Disease Humans Inflammation/genetics/*immunology/pathology *Polymorphism Single Nucleotide Receptors Interleukin/*genetics Urinary Bladder Neoplasms/genetics/*immunology/pathology Bladder urothelial carcinoma Gene polymorphism Interleukin 17 Interleukin 23 Interleukin-23 receptor Natural killers Tumour-associated macrophages

Carcinoma Transitional Cell/*classification/*genetics/mortality Humans Predictive Value of Tests Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*classification/*genetics/mortality Bladder cancer Molecular classification Molecular subtype Prognosis Progression Urothelial carcinoma

Carcinoma Transitional Cell/*drug therapy Humans Prognosis Receptors Fibroblast Growth Factor/*antagonists & inhibitors Urinary Bladder Neoplasms/*drug therapy Bladder cancer Fgfr FGFR inhibitors Fgfr3 Progression Urothelial carcinoma

cohort study intravesical recurrence meta-analysis nomogram preoperative urine cytology upper urinary tract urothelial carcinoma commercial or financial relationships that could be construed as a potential conflict of interest.

Aged Biomarkers/*blood C-Reactive Protein/analysis Cystectomy/*methods Female Humans Leukocyte Count Lymphocytes/pathology Male Middle Aged Neutrophils/pathology Platelet Count Preoperative Period Prognosis Proportional Hazards Models Retrospective Studies Urinary Bladder Neoplasms/blood/*mortality/*surgery Hematologic biomarker Meta-analysis Urothelial carcinoma of the bladder

Administration Intravesical BCG Vaccine/therapeutic use *Carcinoma in Situ/diagnosis/therapy Female Humans Male Neoplasm Invasiveness *Urinary Bladder Neoplasms/diagnosis/pathology/therapy *Urology *BCG unresponsive *Bacillus Calmette-Guerin (BCG) *Bladder cancer *Cystoscopy *Diagnosis *European Association of Urology (EAU) *Follow-up *Guidelines *Intravesical chemotherapy *Prognosis *Radical cystectomy *Transurethral resection (TUR) *Urothelial carcinoma

Adjuvants Immunologic/adverse effects Administration Intravesical BCG Vaccine/adverse effects Humans *Urinary Bladder Neoplasms/drug therapy *Urology Antibiothérapie Antibiotic therapy BCG therapy BCG thérapie Bladder Carcinome urothélial Complications Endovesical instillations Instillations endovésicales Nmibc Tvnim Urothelial carcinoma Vessie

Carcinoma Transitional Cell/epidemiology/*pathology Disease Progression Humans Neoplasm Invasiveness Neoplasm Recurrence Local/epidemiology Neoplasm Staging Prognosis Urinary Bladder Neoplasms/epidemiology/*pathology Bladder cancer Progression Staging Substage T1 Urothelial carcinoma pT1

Radical cystectomy Vi-rads muscle-invasive bladder cancer urothelial carcinoma